by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
The use of splenectomy has declined in recent years with the introduction of additional medications for the treatment of patients with immune throm......READ MORE
by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
Therapy for patients with immune thrombocytopenia (ITP) should be chosen based on a variety of factors, including the presence of bleeding, platele......READ MORE
by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
Clinical trials have demonstrated that thrombopoietin receptor agonists (TPO-RAs) are safe and effective in the treatment of chronic immune thrombo......READ MORE
by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
Although the subject of multiple scientific studies and despite the emergence of novel treatment options that might help understand it, the pathoge......READ MORE
by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
Bleeding is the most clinically important outcome in immune thrombocytopenia (ITP), and therefore the goal of therapy in patients with ITP is to tr......READ MORE
by Adam Cuker, MD, MS, Terry Gernsheimer, MD, Howard A. Liebman, MD
Immune thrombocytopenia (ITP) is often chronic and refractory to treatment. A chart review of patients with treatment-refractory chronic ITP who we......READ MORE
